RE:AGM, BoD and CEOValuation has been the top priority for a while now and they can't even keep it stable let alone inflate it. Phil, the fluffing methodology doesn't apply to inflating share price as it would with other things, it actually works the opposite.
Depending on how the AGM goes and what news is released before it will determine my future in this stock. I think there is way too much resitance now and the only thing that'll break through it is unless the news is that there are more patients off of insulin coupled with a solid deal with a bio/med-tech company with upfront $.
Realistically, my guess is a few of the following happen.
1. Full study of 7 still not enrolled.
2. Patients 4, 5, 6 will not have been in the study long enough for any data.
3. Reduction in hypoglycemic episodes for patients 2, 3 and C-Peptide but no insulin independance. They will require portal vein injection as per the study design.
4. Another collaboration with a named pharma company but not the big deal we are all expecting.
5. Some more fluff presentations and talk about the Thyroid clinical.
6. Another management hire.
And as for share price, I think it will remain stagnant with a 10-20 cent deviation.